181 related articles for article (PubMed ID: 23549322)
1. Development of drug loaded nanoparticles for tumor targeting. Part 2: Enhancement of tumor penetration through receptor mediated transcytosis in 3D tumor models.
El-Dakdouki MH; Puré E; Huang X
Nanoscale; 2013 May; 5(9):3904-11. PubMed ID: 23549322
[TBL] [Abstract][Full Text] [Related]
2. Development of drug loaded nanoparticles for tumor targeting. Part 1: Synthesis, characterization, and biological evaluation in 2D cell cultures.
El-Dakdouki MH; Puré E; Huang X
Nanoscale; 2013 May; 5(9):3895-903. PubMed ID: 23529646
[TBL] [Abstract][Full Text] [Related]
3. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
Hu D; Mezghrani O; Zhang L; Chen Y; Ke X; Ci T
Int J Nanomedicine; 2016; 11():5125-5147. PubMed ID: 27785019
[TBL] [Abstract][Full Text] [Related]
4. Endosomal pH-Responsive Fe-Based Hyaluronate Nanoparticles for Doxorubicin Delivery.
Bae Y; Kim Y; Lee ES
Molecules; 2021 Jun; 26(12):. PubMed ID: 34200716
[TBL] [Abstract][Full Text] [Related]
5. Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates.
Cai S; Alhowyan AA; Yang Q; Forrest WC; Shnayder Y; Forrest ML
J Drug Target; 2014 Aug; 22(7):648-57. PubMed ID: 24892741
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting.
Song S; Qi H; Xu J; Guo P; Chen F; Li F; Yang X; Sheng N; Wu Y; Pan W
Pharm Res; 2014 Nov; 31(11):2988-3005. PubMed ID: 24842660
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
[TBL] [Abstract][Full Text] [Related]
9. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
Lin CW; Lu KY; Wang SY; Sung HW; Mi FL
Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting mesoporous silica nanoparticles for inhibiting tumour cell invasion and metastasis.
Li W; Guo Z; Zheng K; Ma K; Cui C; Wang L; Yuan Y; Tang Y
Int J Pharm; 2017 Dec; 534(1-2):71-80. PubMed ID: 28958879
[TBL] [Abstract][Full Text] [Related]
11. Using hyaluronic acid-functionalized pH stimuli-responsive mesoporous silica nanoparticles for targeted delivery to CD44-overexpressing cancer cells.
Wang Z; Tian Y; Zhang H; Qin Y; Li D; Gan L; Wu F
Int J Nanomedicine; 2016; 11():6485-6497. PubMed ID: 27980406
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
Zhang J; Sun Y; Tian B; Li K; Wang L; Liang Y; Han J
Colloids Surf B Biointerfaces; 2016 Aug; 144():293-302. PubMed ID: 27107383
[TBL] [Abstract][Full Text] [Related]
13. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy.
Edelman R; Assaraf YG; Levitzky I; Shahar T; Livney YD
Oncotarget; 2017 Apr; 8(15):24337-24353. PubMed ID: 28212584
[TBL] [Abstract][Full Text] [Related]
15. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy.
Li J; Li M; Tian L; Qiu Y; Yu Q; Wang X; Guo R; He Q
Int J Pharm; 2020 Mar; 578():119122. PubMed ID: 32035259
[TBL] [Abstract][Full Text] [Related]
16. Dual CD44 and folate receptor-targeted nanoparticles for cancer diagnosis and anticancer drug delivery.
Lee JY; Termsarasab U; Park JH; Lee SY; Ko SH; Shim JS; Chung SJ; Cho HJ; Kim DD
J Control Release; 2016 Aug; 236():38-46. PubMed ID: 27320169
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel-loaded redox-sensitive nanoparticles based on hyaluronic acid-vitamin E succinate conjugates for improved lung cancer treatment.
Song Y; Cai H; Yin T; Huo M; Ma P; Zhou J; Lai W
Int J Nanomedicine; 2018; 13():1585-1600. PubMed ID: 29588586
[TBL] [Abstract][Full Text] [Related]
18. NIR and UV-responsive degradable hyaluronic acid nanogels for CD44-targeted and remotely triggered intracellular doxorubicin delivery.
Hang C; Zou Y; Zhong Y; Zhong Z; Meng F
Colloids Surf B Biointerfaces; 2017 Oct; 158():547-555. PubMed ID: 28743090
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronic acid-coated single-walled carbon nanotubes loaded with doxorubicin for the treatment of breast cancer.
Liu D; Zhang Q; Wang J; Fan L; Zhu W; Cai D
Pharmazie; 2019 Feb; 74(2):83-90. PubMed ID: 30782256
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe
Fang Z; Li X; Xu Z; Du F; Wang W; Shi R; Gao D
Int J Nanomedicine; 2019; 14():5785-5797. PubMed ID: 31440047
[No Abstract] [Full Text] [Related]
[Next] [New Search]
